PRE-MEETING SURVEY

In preparation for the upcoming advisory board meeting, we kindly request your insights on the current treatment landscape for early-stage non-small cell lung cancer (eNSCLC) patients within your practice setting.

The following questions are directly relevant to the topics to be addressed during the meeting. Responses from all advisors will be presented during the meeting to serve as a foundation for a productive roundtable discussion.

We sincerely appreciate your valuable time and look forward to hearing your perspectives on this critical topic.



1. In your clinical practice, which of these NSCLC patients would typically receive adjuvant therapy:

T descriptor: ≤1 cm *
T descriptor: >1-2 cm *
T descriptor: >2-3 cm *
T descriptor: >3-4 cm *
T descriptor: >4-5 cm *
T descriptor: >5-7 cm *
T descriptor: Structures *
T descriptor: >7 cm or diaphragm *
T descriptor: Endobronchial: Location/atelectasis 3-4 cm *
T descriptor: Endobronchial: Location/atelectasis 4-5 cm *
T descriptor: T4 (other than >7 cm and diaphragm invasion) *

2. In your clinical practice, which of these NSCLC patients would typically receive neoadjuvant therapy:

T descriptor: ≤1 cm *
T descriptor: >1-2 cm *
T descriptor: >2-3 cm *
T descriptor: >3-4 cm *
T descriptor: >4-5 cm *
T descriptor: >5-7 cm *
T descriptor: Structures *
T descriptor: >7 cm or diaphragm *
T descriptor: Endobronchial: Location/atelectasis 3-4 cm *
T descriptor: Endobronchial: Location/atelectasis 4-5 cm *
T descriptor: T4 (other than >7 cm and diaphragm invasion) *
12. Please study the proposed referral pathway for your respective country here. How does your current referral pathway align with the proposed pathway? *